Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Gains from Investment Securities (2021 - 2024)

Opus Genetics (IRD) has disclosed Gains from Investment Securities for 7 consecutive years, with $26000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $26000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $344000.0, a N/A change, with the full-year FY2023 number at $344000.0, down 88.28% from a year prior.
  • Gains from Investment Securities was $26000.0 for Q4 2023 at Opus Genetics, down from $318000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.1 million in Q4 2021 to a low of $26000.0 in Q4 2023.